At present, cinacalcet hydrochloride is the preferred therapeutic option for lowering PTH levels while maintaining normal serum calcium and phosphorus concentrations, and improving mortality and cardiovascular outcomes in CKD patients [9, 10]. The gene discussed is PTH; the disease is chronic kidney disease.